Product Details
| Product Name:
Labetuzumab |
CAS No.:
219649-07-7 |
| Purity:
95.6% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Labetuzumab |
| Description | Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study of thyroid and colorectal cancer (CRC). |
| In vivo | In vivo, Labetuzumab inhibits tumor growth following a single intravenous administration at a dose of 0.5 mg per rat [1]. |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:109785-20-8
$439.00 / 1mg
-
CAS:108179-91-5
$240.00 / 10mg
-
CAS:1392275-56-7
$39.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States